Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the company will deliver multiple presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 being held April 5-10, 2024, in San Diego, California.Details of the planned presentations are listed below:
*Revolution Medicines Oral Presentations:*
*Title:*
Discovery of RMC-9805, an Oral, RAS(ON) G12D-Selective Covalent Tri-Complex Inhibitor
*Presenter:*
John Knox, Ph.D.
*Abstract Number:*
ND03
*Session:* New Drugs on the Horizon: Part 1
*Date/Time:* 1:45 – 2:00 p.m. PT on April 7, 2024
*Title:* RMC-6236, a RAS(ON) Multi-Selective Tri-Complex Inhibitor
*Presenter:* Elena Koltun, Ph.D., Wei Lin, M.D.
*Session:* KRAS: Broadening the Attack Beyond G12C with Small Molecules and Immuno-Oncology
*Date/Time:* 1:00 – 1:20 p.m. PT on April 9, 2024
*Title:* Combination of RAS(ON) G12C-Selective and Multi-Selective Tri-Complex Inhibitors Overcomes Resistance and Prolongs Durability in Preclinical Models of KRAS^G12C NSCLC
*Presenter:* Xing Wei, Ph.D.
*Abstract Number: * 6585
*Session: * Novel Antitumor Agents 5
*Date/Time:* 2:35 – 2:50 p.m. PT on April 9, 2024
*Revolution Medicines Poster Presentations:*
*Title:*
Potential Biomarkers of Response to the Combination of the RAS(ON) Multi-Selective Inhibitor RMC-6236 Plus Anti-PD-1 Antibody in Preclinical PDAC Models
*Presenter:*
Lillian Seu, Ph.D.
*Abstract Number:*
581/4
*Session:* Immunotherapy
*Date/Time:* 1:30 – 5:00 p.m. PT on April 7, 2024
*Title:* RMC-5127, a First-in-Class, Orally Bioavailable RAS(ON) G12V-Selective Tri-Complex Inhibitor, is CNS-Penetrant and Drives Regressions in Intracranially Implanted KRAS^G12V Xenograft Tumors
*Presenter:* Zhe Chen, M.B.B.S., Ph.D.
*Abstract Number:* 3340/28
*Session:* Novel Antitumor Agents 3
*Date/Time:* 1:30 – 5:00 p.m. PT on April 8, 2024
*Title:* The RAS(ON) Multi-Selective Inhibitor RMC-7977 Blocks Downstream MAPK and PI3K Pathway Activation in KRAS^G12X-Mutant Cancers
*Presenter:* Priyanka Bapat, Ph.D.
*Abstract Number: * 4709/2
*Session: * Other Cellular Mechanisms for Anticancer Drug Action
*Date/Time:* 9:00 a.m. – 12:30 p.m. PT on April 9, 2024
*Collaborator Poster Presentations:*
*Title:*
RTK Signaling and WT RAS Activity as Vulnerabilities in Tumors with Acquired Resistance to GDP-State Selective KRAS^G12C Inhibitors in Preclinical Models
*Lead RevMed Co-Author:* Harshit Shah, Ph.D.
*Abstract Number:*
1924/2
*Session:* Drug Resistance 2: RAS GTPase
*Date/Time:* 9:00 a.m. – 12:30 p.m. PT on April 8, 2024
*Title:* Resistance to RAS-GTP Inhibition in Models of Pancreatic Ductal Adenocarcinoma Arises Downstream of RAS Effectors
*Lead RevMed Co-Author:* Jingjing Jiang, Ph.D.
*Abstract Number:* 1927/5
*Session:* Drug Resistance 2: RAS GTPase
*Date/Time:* 9:00 a.m. – 12:30 p.m. PT on April 8, 2024
Additional information on the AACR Annual Meeting 2024 is available through the AACR website at: https://www.aacr.org/meeting/aacr-annual-meeting-2024/
*About Revolution Medicines, Inc.*
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors for use in combination treatment strategies. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional RAS(ON) mutant-selective inhibitors in the company’s development pipeline include RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C).
CONTACT: Media & Investor Contact
Erin Graves
650-779-0136
egraves@revmed.com